

esmo impact factor

esmo impact factor is a critical metric widely recognized in the oncology research community, reflecting the influence and prestige of the European Society for Medical Oncology's (ESMO) publications. This quantitative measure serves as a benchmark for the quality and reach of scientific articles published under the ESMO banner, impacting researchers, clinicians, and academic institutions alike. Understanding the esmo impact factor is essential for professionals who rely on authoritative sources to guide clinical practice and research in oncology. This article explores the concept of the esmo impact factor, its calculation methodology, significance in the medical field, comparison with other oncology journals, and its role in advancing cancer research. Additionally, the discussion will cover factors influencing the esmo impact factor and how it affects publication strategies for researchers. The following sections provide a comprehensive overview designed to enhance comprehension of this vital indicator.

- Understanding the ESMO Impact Factor
- Calculation and Methodology
- Significance in Oncology Research
- Comparison with Other Oncology Journals
- Factors Influencing the ESMO Impact Factor
- Implications for Authors and Researchers

Understanding the ESMO Impact Factor

The esmo impact factor is a numerical value representing the average number of citations received per paper published in ESMO journals within a specific time frame, typically two years. It provides insight into the journal's academic influence and the relevance of its published content to the oncology community. ESMO, as a leading organization in medical oncology, publishes several journals that contribute to disseminating cutting-edge cancer research, clinical trials, and therapeutic guidelines. The impact factor is often seen as a proxy for the journal's prestige and is used by authors to decide where to submit their manuscripts.

Definition and Purpose

The impact factor quantifies how often articles in a journal are cited in other scholarly works, indicating the journal's importance in its field. For ESMO journals, this metric helps gauge the dissemination and uptake of oncology research findings, reflecting the journal's role in shaping clinical oncology practices worldwide.

ESMO Journals Overview

ESMO publishes multiple journals, including the flagship journal "Annals of Oncology," which has a notable esmo impact factor. These journals cover a broad range of topics such as cancer biology, clinical trials, treatment guidelines, and patient care, contributing to the comprehensive nature of ESMO's scholarly output.

Calculation and Methodology

The esmo impact factor is derived using a standardized formula applied by citation indexing organizations. Understanding how it is calculated is essential for interpreting its value accurately.

Formula for Impact Factor

The impact factor is calculated as follows:

1. Count the total citations in the current year to articles published in the journal during the previous two years.
2. Divide this number by the total number of "citable items" published in the journal during those two years.

This ratio provides the average number of citations per article, representing the impact factor.

Time Frame and Data Sources

The data for calculating the esmo impact factor is typically collected from citation databases such as Web of Science. The two-year citation window reflects recent research impact and relevance, though some critiques suggest longer windows might better capture influence in clinical fields.

Significance in Oncology Research

The esmo impact factor holds considerable significance for oncology researchers, clinicians, and institutions by serving as an indicator of research quality and journal reputation.

Guiding Research and Clinical Practice

High-impact ESMO journals often publish influential studies that contribute to evidence-based oncology practice. The esmo impact factor helps clinicians identify reliable sources for updated treatment protocols and emerging therapies.

Academic and Professional Recognition

Researchers benefit from publishing in journals with a strong esmo impact factor, as it enhances visibility, credibility, and academic advancement. Institutions also use this metric to evaluate research performance and allocate funding.

Comparison with Other Oncology Journals

In the competitive landscape of oncology publishing, the esmo impact factor provides a benchmark against other leading journals in the field.

Position Among Oncology Journals

ESMO journals, particularly "Annals of Oncology," consistently rank among the top oncology journals by impact factor. This ranking reflects their influence compared to other publications such as the Journal of Clinical Oncology or Cancer Research.

Strengths and Limitations Compared to Peers

While the esmo impact factor highlights the journal's strengths in clinical relevance and research quality, it also shares limitations common to impact factors, such as bias towards review articles and short-term citation windows. Comparing it alongside other metrics provides a more nuanced understanding of journal influence.

Factors Influencing the ESMO Impact Factor

Several elements affect the esmo impact factor, shaping its fluctuations and trends over time.

Publication Volume and Article Types

The number of articles published and the inclusion of high-citation article types like reviews or guidelines can significantly impact the esmo impact factor. Journals strategically balance content to optimize citation potential.

Research Trends and Citation Practices

Emerging topics in oncology, such as immunotherapy or precision medicine, may attract more citations, elevating the impact factor. Additionally, citation behaviors within the oncology community influence this metric.

Implications for Authors and Researchers

The esmo impact factor plays a pivotal role in shaping publication decisions and research dissemination strategies.

Choosing a Publication Venue

Authors often prioritize submitting manuscripts to journals with a high esmo impact factor to maximize visibility and impact. Understanding this metric aids in selecting the most appropriate journal for their work.

Enhancing Research Impact

Researchers can leverage awareness of the esmo impact factor to align their studies with topics of high interest, collaborate on multidisciplinary projects, and engage with ESMO's editorial standards to increase the likelihood of publication and citation.

- Improved career prospects through publication in high-impact journals
- Increased dissemination of research findings within the oncology community
- Greater contribution to evidence-based clinical practice

Frequently Asked Questions

What is the ESMO impact factor?

The ESMO impact factor refers to the impact factor of journals published by the European Society for Medical Oncology (ESMO), which reflects the average number of citations to recent articles published in these journals.

Which journal has the highest ESMO impact factor?

The Annals of Oncology, the official journal of ESMO, typically holds the highest impact factor among ESMO journals, reflecting its influence in the field of oncology research.

How is the ESMO impact factor calculated?

The ESMO impact factor is calculated based on the number of citations received in a particular year by articles published in the journal during the previous two years, divided by the total number of articles published in those two years.

Why is the ESMO impact factor important for researchers?

The ESMO impact factor is important for researchers as it indicates the prestige and influence of ESMO journals, helping them decide where to publish and assess the reach of their research within the oncology community.

Has the ESMO impact factor changed recently?

ESMO journal impact factors may fluctuate yearly based on citation patterns; researchers should check the latest Journal Citation Reports for the most current figures.

Are ESMO journals considered high-impact in oncology?

Yes, ESMO journals, especially *Annals of Oncology*, are considered high-impact and reputable sources in the field of oncology.

Where can I find the current ESMO impact factor?

The current ESMO impact factor can be found in the Journal Citation Reports released annually by Clarivate Analytics or on the official ESMO journal websites.

Does the ESMO impact factor influence clinical practice?

While the ESMO impact factor itself is a metric, high-impact ESMO journals publish influential research that can significantly impact clinical oncology practice and guidelines.

Can the ESMO impact factor be used to compare journals?

Yes, the ESMO impact factor can be used to compare the relative citation impact of ESMO journals with other oncology journals, but it should be considered alongside other qualitative factors.

Additional Resources

1. Understanding ESMO Impact Factor: A Comprehensive Guide

This book provides an in-depth analysis of the European Society for Medical Oncology (ESMO) impact factor, explaining its significance in the field of oncology research. It covers the methodology behind impact factor calculations and how ESMO journals compare with others in the medical community. Readers will gain insights into using impact factors to evaluate research quality and journal prestige.

2. The Role of ESMO Journals in Cancer Research

Focusing on the influential journals published under the ESMO umbrella, this book explores their contribution to advancing cancer research worldwide. It discusses trends in publication, citation metrics, and how impact factors reflect the journals' scientific influence. The text also examines the challenges and future directions for ESMO journals in a rapidly evolving research environment.

3. Impact Factors and Oncology Publishing: The Case of ESMO

This title delves into the broader topic of impact factors within oncology publishing, with a special emphasis on ESMO's journals. It addresses the pros and cons of using impact factors as a measure of scientific merit and how ESMO journals have navigated these metrics to maintain high standards. The book is essential for authors, editors, and researchers interested in publication strategies.

4. ESMO Impact Factor Trends: Analysis and Implications

Providing a detailed statistical review, this book tracks the impact factor trends of ESMO journals over the past decades. It interprets changes in citation patterns and discusses the implications for researchers and clinicians relying on these journals for cutting-edge oncology information. The analysis also sheds light on the factors influencing impact factor fluctuations.

5. Maximizing Your Research Impact in ESMO Journals

Designed for researchers aiming to publish in ESMO journals, this practical guide offers strategies to enhance the visibility and impact of their work. It covers manuscript preparation, choosing the right journal, and understanding how impact factors can affect publication decisions. The book also provides tips on promoting published research to increase citation rates.

6. ESMO Journals: Editorial Perspectives on Impact Factor

This collection of essays from editors of various ESMO journals gives insider views on the role impact factors play in editorial policies and decision-making. It discusses balancing scientific rigor with the pursuit of higher impact metrics and the ethical considerations involved. Readers will appreciate the transparent discussion about the challenges in managing prestigious oncology journals.

7. Comparative Study of ESMO and Other Oncology Journal Impact Factors

This comparative study examines how ESMO journals rank against other leading oncology journals worldwide based on impact factors. It analyzes factors contributing to these rankings, such as publication frequency, article types, and citation behaviors. The book offers valuable insights for researchers deciding where to submit their work for maximum exposure.

8. *Future Perspectives on ESMO Impact Factor and Scientific Publishing*

Looking ahead, this book explores potential changes in how impact factors are calculated and used, particularly concerning ESMO journals. It discusses emerging alternative metrics, open access trends, and the evolving landscape of scientific publishing. The author provides predictions and recommendations for maintaining the relevance and integrity of impact factors.

9. *ESMO Impact Factor Explained: A Resource for Oncology Professionals*

This accessible resource breaks down the concept of impact factors specifically for oncology professionals unfamiliar with bibliometrics. It explains why ESMO impact factors matter for clinical practice, research funding, and career advancement. With clear examples and FAQs, the book serves as a handy reference for anyone involved in oncology research or education.

Esmo Impact Factor

Find other PDF articles:

<https://explore.gcts.edu/games-suggest-003/files?dataid=Xmh32-8823&title=no-mercy-walkthrough.pdf>

esmo impact factor: *ESMO ... Proceedings* , 2003

esmo impact factor: *Proceedings from ESMO ...* , 2000

esmo impact factor: *ESMO ...* , 1980

esmo impact factor: *ESMO-95 Proceedings* , 1995

esmo impact factor: *Factors that impact the survival of non-small cell lung cancer* Kristin Higgins, Jessy Deshane, Fiona Hegi-Johnson, 2023-03-15

esmo impact factor: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae? Kulmira Nurgali, R. Thomas Jagoe, Raquel Abalo, 2018-06-12
Advances in anti-cancer chemotherapy over recent years have led to improved efficacy in curing or controlling many cancers. Some chemotherapy-related side-effects are well recognized and include: nausea, vomiting, bone marrow suppression, peripheral neuropathy, cardiac and skeletal muscle dysfunction and renal impairment. However, it is becoming clearer that some chemotherapy-related

adverse effects may persist even in long term cancer survivors. Problems such as cognitive, cardiovascular and gastrointestinal dysfunction, and neuropathy may lead to substantial long term morbidity. Despite improvements in treatments to counteract acute chemotherapy-induced adverse effects, they are often incompletely effective. Furthermore, counter-measures for some acute side-effects and many potential longer term sequelae of anti-cancer chemotherapy have not been developed. Thus, new insights into prevalence and mechanisms of cancer chemotherapy-related side effects are needed and new approaches to improving tolerance and reduce sequelae of cancer chemotherapy are urgently needed. The present Research Topic focuses on adverse effects and sequelae of chemotherapy and strategies to counteract them.

esmo impact factor: Recent Advances in Endometriosis: from Bench to Clinical Application Achmad Kemal Harzif, Budi Wiweko , Iveta Yotova, Mila Maidarti, 2025-02-27 Endometriosis is a benign and enigmatic disease estimated to affect 6–10% of women of reproductive age. It has been associated with two significant problems, chronic pelvic pain and subfertility. Endometriosis is an estrogen-dependent disorder described as the presence of endometrial glands and stroma outside the uterine cavity. This disease may have undesirable consequences on a woman's physical and emotional well-being. Accordingly, it may attenuate women's quality of life and productivity. Likewise, Endometriosis can cause substantial economic and social problems for patients, families, and society. Despite its high prevalence, cost, and many published articles, the pathogenesis of Endometriosis remains controversial due to the lack of robust evidence. This issue may consequently restrict our understanding of the disease and decelerate innovation in diagnostic and treatment options. It is now well accepted that a combination of genetic, hormonal, and immunological factors may contribute to the development of Endometriosis. Endometriosis treatments have been primarily focused on alleviating the symptoms and not the underlying mechanisms of the disease. The nature of individual influencing factors, immune system and peritoneal cavity of women with Endometriosis remains to be elucidated. Although the advances in research over the years have enhanced our understanding associated with hormones and their receptors, immune disorder, the principle of hormonal treatments for Endometriosis, comprehensive and interdisciplinary approaches to disease management, and awareness for patients and health care providers are compulsory to eradicate stigma, intensify an accurate diagnosis and permit for new developments.

esmo impact factor: Bioregenerative Life-Support Systems for Crewed Missions to the Moon and Mars Cyprien Verseux, Jean-Pierre Paul de Vera, Natalie Leys, Lucie Poulet, 2022-10-20

esmo impact factor: Hematopoietic Growth Factors in Oncology George Morstyn, MaryAnn Foote, Graham J. Lieschke, 2004-02-05 Whether to promote platelet recovery or to ameliorate the complications of cancer and the side effects of chemotherapy, hematopoietic growth factors (HGFs) now account for more than \$5 billion per year of the US health care budget. In *Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics*, leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and non-Hodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietic factors, thrombopoietic factors, and stem-cell factor and its receptor, c-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonists in oncology. Comprehensive and up-to-date, *Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Practice* offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombocytopenia in patients with malignant and nonmalignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit.

esmo impact factor: *Textbook of Gastrointestinal Oncology* Suayib Yalcin, Philip A. Philip, 2019-09-05 This textbook discusses core principles and practices in gastrointestinal oncology and

covers a wide range of practice areas such as pathology and radiologic images, epidemiology, genetics, staging, multidisciplinary management of specific gastrointestinal cancer, and pathology for each primary tumor site. The comprehensive coverage makes Textbook of Gastrointestinal Oncology a useful resource for the practitioner wishing to gain a greater understanding of the principles of managing malignant gastrointestinal disease, as well as medical oncology fellows, surgeons, radiation oncologists, gastroenterologists and fellows, and residents.

esmo impact factor: Best of Five MCQS for the European Specialty Examination in Gastroenterology and Hepatology Thomas Marjot, Colleen McGregor, Tim Ambrose, 2021 The new edition of iThe Best of Five MCQS for the European Specialty Examination in Gastroenterology and Hepatology/i is a question book designed to assist in preparations for the ESEGH. The book has been fully updated to reflect the structure and content of the new examination introduced in 2018 and the most recent guidelines.

esmo impact factor: Evaluative Informetrics: The Art of Metrics-Based Research Assessment Cinzia Daraio, Wolfgang Glänzel, 2020-07-23 We intend to edit a Festschrift for Henk Moed combining a “best of” collection of his papers and new contributions (original research papers) by authors having worked and collaborated with him. The outcome of this original combination aims to provide an overview of the advancement of the field in the intersection of bibliometrics, informetrics, science studies and research assessment.

esmo impact factor: Colorectal Cancer Gowhar Rashid, Deena ElSORI, Rana Ahmed Youness, 2025-05-13 This concise text examines the contribution of genetic research to clinical practice in colorectal cancer. It delves into the underlying molecular mechanisms and the genetic and environmental factors contributing to colorectal cancer, as well as into advances in personalized therapies, targeted interventions, and biomarker-based approaches. By providing a comprehensive overview of the subject, the book aims to bridge the gap between scientific research and clinical practice, offering valuable insights to researchers, clinicians, and healthcare professionals dedicated to combating colorectal cancer and improving patient outcomes. Unites scientific discovery to clinical practice Offers a practical resource for the multidisciplinary team treating colorectal cancer patients Presents the state of the art in clinical management

esmo impact factor: PET/CT in Cancer: An Interdisciplinary Approach to Individualized Imaging Mohsen Beheshti, Werner Langsteger, Alireza Rezaee, 2017-05-25 Edited, authored, and reviewed by an expert team of oncologists and nuclear physicians/radiologists, this one-of-a-kind title helps you make the most of the critical role PET/CT plays in cancer staging and therapeutic responses to individualized treatments. Drs. Mohsen Beheshti, Werner Langsteger, and Alireza Rezaee place an emphasis on cutting-edge research and evidence-based practice, ensuring that you're up to date with every aspect of this fast-changing field. For each tumor entity, you'll find authoritative discussions of background, pathology, common pattern of spread, TNM classification, clinical guidelines, discussion, evidence-based recommendations, key points, and pitfalls. - Contains 130 teaching cases with high-quality PET/CT images. - Presents clear, practical guidance from multiple experts across subspecialties: nuclear medicine, oncology, oncologic surgery, radiation oncology, and clinical research. - Includes separate, comprehensive chapters on head and neck, lung, breast, esophageal/gastric, pancreas/neuroendocrine, colorectal, hepatobiliary, lymphoma, gynecologic, prostate, melanoma, and brain cancers. - Features short reviews of clinical aspects of different cancers, primary diagnostic procedures, and recommendations regarding PET/CT from ESMO and NCCN. - Helps to reveal positive outcomes or potential deficits or weaknesses in an individual plan of care, allowing for better outcomes in patient care, future cancer research, and application of radiotracers beyond 18F-FDG.

esmo impact factor: Successes and Limitations of Targeted Cancer Therapy S. Peters, R.A. Stahel, 2014-02-19 The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient's tumor. Targeting specific molecular

pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies.

esmo impact factor: Gliomas , 2016-03-02 Researchers' knowledge of gliomas continues to advance rapidly at both the basic and translational levels, and Gliomas provides a thorough overview of the evolving fields of tumor biology and clinical medicine as they relate to our understanding of brain tumors. Gliomas reviews the current paradigms that underlie these fields, beginning with the molecular epidemiology of glioma susceptibility and prognosis through population-based science and genome-wide association studies. The book's discussion of imaging modalities extends beyond advances in anatomical imaging to include metabolic and physiological studies. This work provides thorough discussion of the clinical view of tumors, ranging from the presentation of the patient to surgical management, and covers all therapeutic options for patient care, including chemotherapy, targeted molecular therapies, immunotherapies, and even personalized approaches to impact the set of lesions. Additionally, the book discusses radiotherapy with regard to the many options available to treat patients using myriad fractionated techniques with various sources. Finally, Gliomas reviews issues specific to the quality of life for patients, and techniques for maximizing the effect of caregivers. Edited and authored by premier researchers from around the world, Gliomas is a comprehensive reference for clinicians and researchers seeking the most up-to-date information on gliomas, and a guide to the best ways to effectively manage glioma patients and their care. - Synthesizes widely dispersed information on the management of gliomas into one comprehensive resource - Chapters written by international authors who are preeminent researchers in the field - Fully explores the therapeutic options for patient care, from chemotherapy to radiotherapy to personalized approaches

esmo impact factor: TNFRSF Agonists: Mode of action and therapeutic opportunities
Nataša Obermajer, Harald Wajant, Adam Zwolak, 2023-12-04 The receptors of the TNFRSF (TNFRs) are of overwhelming importance in the regulation of the immune system but are also involved in the induction of apoptotic cell death or cell survival and proliferation, making them excellent therapeutic targets for cancer but also other diseases. TNFRSF members provide crucial co-stimulatory signals to many if not all immune effector cells. Each co-stimulatory TNFR has a distinct expression profile and a unique functional impact on various types of cells and at different stages of the immune response. For example, the two receptors of TNF, TNF receptor-1 (TNFR1) and TNF receptor-2 (TNFR2), regulate the interaction of the various types of immune cells and also the interplay of the latter with practically any type of non-hematopoietic cells; CD40 stimulates antigen-presenting cells; CD27, OX40, 41BB, GITR, HVEM and RANK costimulate T cells; BCMA, TACI, and BaffR regulate B-cell maturation; CD95 and the two death receptors of TRAIL contribute to tumor surveillance and Fn14, EDAR and XEDAR have been implicated in tissue regeneration and development. Correspondingly, exploiting TNFR-mediated signaling for the therapy of cancer but also of non-cancerous diseases is a major field of interest. A further application of TNFRSF signaling is the incorporation of the intracellular co-stimulatory domain of a TNFRSF receptor into so-called Chimeric Antigen Receptor (CAR) constructs for CAR-T cell therapy, the most prominent example of which is the 4-1BB co-stimulatory domain included in the clinically approved product Kymriah. The goal of this research topic is to provide concise overview of the recent advances in our understanding of agonists targeting TNFRSF and their potential therapeutic use, in particular in cancers. The focus of the series of research and review articles includes but is not limited to the biology of TNFRSF receptors in distinct immune cell populations, structure-function relationship of

TNFRSF agonists, current preclinical and clinical knowledge of co-stimulatory TNFR agonists, opportunities for next generation TNFRSF therapeutics alone or in combination with immune checkpoint molecules. We encourage the submission of original research articles supported by pre-clinical data. Review articles will also be considered. Data should consist of anti-tumor activity analyses encompassing various murine or humanized mouse models, assessment of TNFRSF targeting in translational ex vivo primary human tumor tissue settings, or innovative single cell or spatial analysis of TNFRSF expression and association with tumor progression in patient material. Submissions should not be limited to the in vitro evaluation of TNFRSF signaling. We expect submissions based on (but not limited to): • TNFRSF signaling in shaping the immune contexture for anti-tumor immunity. • Engaging cytotoxic TNFRSF signaling to treat cancer. • Engaging TNFRSF signaling in non-cancerous diseases. • Immunobiology of TNFRSF receptors in specific immune cell populations, eg regulatory T cells (TNFR2, 41BB, TNFRSF25, ..), dendritic cells (CD40, RANK ...), NK cells ... • Critical aspects of TNFRSF structure-function and receptor clustering . • Balancing agonistic strength with FcγR affinity in the context of opportunities for next generation anti-TNFR antibodies with improved pharmacologic properties. • TNFRSF-based agonists with conditional or constitutive agonism. • Potential of simultaneous blockade of immune checkpoint molecules and co-stimulation of the TNFRSF in improving anti-tumor immunity. • Bispecific TNFR agonists. • anti-TNF-α agents in cancer immunotherapy. • Prominence and key features of TNFRSF members (4-1BB, OX40, CD27, CD40, HVEM, and GITR) as co-stimulatory domains in CAR-T cell therapy . • Current preclinical and clinical knowledge of co-stimulatory TNFR antibodies. Topic Editor Nataša Obermajer is a full time employee and shareholder of Janssen R&D, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Topic Editor Dr. Adam Zwolak is employed by Janssen R&D; The University of Würzburg has filed patent applications for TNFR2, Fn14 and CD40 agonists and bispecific anti-TNFR antibody formats with conditional activity with Dr. Harald Wajant as co-inventor. The University of Würzburg receives funding from Dualyx NV for the development of TNFR2 agonists

esmo impact factor: Frontiers in Ovarian Cancer Science Hidetaka Katabuchi, 2017-09-04 This volume presents the latest advances and the current status of our understanding regarding ovarian cancer, addressing both the basic and clinical aspects of the disease. In terms of basic medicine, the WHO Classification of Tumors of Female Reproductive Organs was revised in 2014, and that version addresses several new concepts and histopathological classifications not previously included. One of the most revolutionary breakthroughs concerns the genesis of epithelial ovarian tumors, shifting the focus from the ovarian surface epithelium to serous tubal intraepithelial carcinomas. Clinically, the mortality rate of epithelial ovarian cancer has gradually increased over the past few decades, making it essential to pursue multidisciplinary treatment and apply novel techniques such as neoadjuvant chemotherapy in daily clinical practice. The primary clinical task is the effective treatment of recurrent ovarian cancer with early palliative medicine. Fertility-sparing surgery may also be pursued depending on histologic subtypes, stage, extent of disease, and preexisting ovarian reserve with the concept of oncofertility. On the basis of the considerations described above, each expert author elucidates the science of ovarian cancer in detail, thus providing a collection that will benefit young medical oncologists and seasoned gynecologists and obstetricians alike.

esmo impact factor: Cancer Biomarkers: Molecular Insights into Diagnosis, Prognosis, and Risk Prediction Matteo Becatti, Shaoquan Zheng, Giuseppe Bronte, 2025-07-30 This collection of articles offers a comprehensive overview of recent advances in cancer biomarkers and their importance in precision oncology, spanning a diverse array of tumor types and clinical challenges. The assembled studies highlight breakthroughs in early detection, prognostic and predictive markers, and novel therapeutic targets, with a strong emphasis on integrating molecular and bioinformatics approaches. Topics include the clinical potential of autoantibodies in non-small cell lung cancer, the regulatory mechanisms and prognostic significance of proteins such as HJURP and DAP3 in gastric and liver cancers, the use of circulating tumor cells for non-invasive genetic testing in colorectal cancer, and the emerging role of TEM8 as a solid tumor biomarker. Additionally, the

abstracts explore the value of multidimensional risk modeling, immune pathway analyses (including STING signaling), the prognostic utility of the glucose-to-lymphocyte ratio, and the diagnostic significance of advanced imaging biomarkers like ADC values in rectal cancer. The collection also addresses particular clinical scenarios, such as the unique diagnostic challenges in Ewing sarcoma and the overlap of molecular pathways between lung cancer and myocardial infarction, while underlining the critical need for personalized therapy guided by precise molecular features. Together, these studies underscore the momentum and breadth of cancer biomarker research, with direct implications for improving early diagnosis, treatment stratification, and patient outcomes.

esmo impact factor: Symptom Management Guidelines for Oncology Nursing Anne Katz, 2024-03-16 Uses a systems-based approach to for rapid access to symptoms commonly experienced during and after treatment Written in an easy-to-read format for use in daily practice, this evidence-based resource delivers the most current, comprehensive clinical guidelines for key pharmaceutical and supportive interventions with patients suffering from cancer. The book is distinguished by its systems-based approach which addresses--from head-to-toe--the symptoms commonly experienced by cancer patients during and after treatment. Each section of the book offers a comprehensive examination of common cancer symptoms along with clinical guidance on the most effective means of management. Sections cover general symptoms (fatigue, pain, alopecia) as well as those experienced in specific areas including gastrointestinal, genitourinary, pulmonary, neurological, cutaneous, and psychosocial. Chapters within each section consistently address such salient issues as prevalence, contributing factors, assessment, and management, along with a supporting case study and review questions to reinforce information. Textboxes and callouts pinpoint critical information throughout. Ancillaries include an Instructor's PowerPoint slide deck. Key Features: Delivers evidence-based guidance for oncology specialists and for those who care for individuals with cancer in their general practice Provides the most up-to-date information on key pharmaceutical and supportive interventions Highlights critical information with textboxes and callouts Includes a case study and review questions in each chapter to reinforce content Presents information based on established and validated guidelines from NCCN, ONS, ASCO, NCI, and others Includes PowerPoint slides for use by staff educators

Related to esmo impact factor

ESMO ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

ESMO Annual Report 2023 ESMO Vision 2025: standing by those who care about cancer Driven by a shared determination to secure the best possible outcomes for patients with cancer, ESMO is committed to caring for

Log in to your ESMO Account Log in to your ESMO AccountUsername *
Meeting CalendarOncologyPRO

ESMO ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

ESMO Annual Report 2023 ESMO Vision 2025: standing by those who care about cancer Driven by a shared determination to secure the best possible outcomes for patients with cancer, ESMO is committed to caring for

Log in to your ESMO Account Log in to your ESMO AccountUsername *
Meeting CalendarOncologyPRO

ESMO ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

ESMO Annual Report 2023 ESMO Vision 2025: standing by those who care about cancer Driven by a shared determination to secure the best possible outcomes for patients with cancer, ESMO is committed to caring for

Log in to your ESMO Account Log in to your ESMO AccountUsername *
Meeting CalendarOncologyPRO

ESMO ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

ESMO Annual Report 2023 ESMO Vision 2025: standing by those who care about cancer Driven by a shared determination to secure the best possible outcomes for patients with cancer, ESMO is committed to caring for

Log in to your ESMO Account Log in to your ESMO AccountUsername *
Meeting CalendarOncologyPRO

ESMO ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

ESMO Annual Report 2023 ESMO Vision 2025: standing by those who care about cancer Driven by a shared determination to secure the best possible outcomes for patients with cancer, ESMO is committed to caring for

Log in to your ESMO Account Log in to your ESMO AccountUsername *
Meeting CalendarOncologyPRO

Back to Home: <https://explore.gcts.edu>